|
|
|
|
| |
|
|
| Jin,B.; Wu,B.W.; Wen,Z.C.; Shi,H.M.; Zhu,J.. |
| Idiopathic dilated cardiomyopathy (IDC) has been hypothesized as a multifactorial disorder initiated by an environment trigger in individuals with predisposing human leukocyte antigen (HLA) alleles. Published data on the association between HLA-DR3 antigen and IDC risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Studies were identified by searching the PUBMED and Embase database (starting from June 2015). A total of 19 case-control studies including 1378 cases and 10383 controls provided data on the association between HLA-DR3 antigen and genetic susceptibility to IDC. Overall, significantly decreased frequency of HLA-DR3 allele (OR=0.72; 95%CI=0.58-0.90; P=0.004) was found in patients with IDC... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: HLA-DR; Dilated cardiomyopathy; Polymorphism; Meta-analysis. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000400708 |
| |
|
|
| Chan,L.W.; Luo,X.P.; Ni,H.C.; Shi,H.M.; Liu,L.; Wen,Z.C.; Gu,X.Y.; Qiao,J.; Li,J.. |
| High levels of low-density lipoprotein cholesterol (LDL-C) enhance platelet activation, whereas high levels of high-density lipoprotein cholesterol (HDL-C) exert a cardioprotective effect. However, the effects on platelet activation of high levels of LDL-C combined with low levels of HDL-C (HLC) have not yet been reported. We aimed to evaluate the platelet activation marker of HLC patients and investigate the antiplatelet effect of atorvastatin on this population. Forty-eight patients with high levels of LDL-C were enrolled. Among these, 23 had HLC and the other 25 had high levels of LDL-C combined with normal levels of HDL-C (HNC). A total of 35 normocholesterolemic (NOMC) volunteers were included as controls. Whole blood flow cytometry and platelet... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Low-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Platelet activation; Statins; PAC-1; CD62p. |
| Ano: 2015 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2015000200167 |
| |
|
|
|
